《肝胆肿瘤分子诊断临床应用专家共识》解读

Interpretation of the consensus on clinical application of molecular diagnosis of hepatobiliary carcinoma

随着测序技术、靶向及免疫治疗在肝胆肿瘤领域的发展和普及,分子标志物在肝胆肿瘤的早期诊断、精准治疗及改善预后中发挥着越来越大的作用。为规范及指导肝胆系统原发恶性肿瘤相关分子标志物的临床应用,肝胆领域内多个专家协会结合中国实际,经过反复讨论形成了《肝胆肿瘤分子诊断临床应用专家共识》。本文将从诊断、治疗、质量控制等环节阐述共识要点,并结合肝胆肿瘤最新指南及研究结果,详解分子标志物的进展及部分争议内容,以期为肝胆肿瘤个体化诊疗提供科学依据,使患者更大程度获益。

Molecular biomarkers play a significant role in the early diagnosis of,the provision of precision therapy for,and the prognosis of hepatobiliary carcinoma.The popularity of sequencing,targeted therapy and immunotherapy for hepatobiliary carcinoma has also increased.To standardize and guide the application of molecular biomarkers in clinical practice,multiple hepatobiliary expert groups have published a consensus on the clinical application of molecular diagnosis of hepatobiliary carcinoma based on in-depth discussions,according to the current situation in China.This article will interpret the core recommendations from the consensus for hepatobiliary carcinoma diagnosis,treatment,and related quality control.We will also provide an update on progression and clarify some of the controversies surrounding molecular biomarkers based on the latest clinical guidance and research,with the aim of offering scientific references and guidance for personalized treatment decisions as well as maximizing the benefits to patients.